Economic Evaluation of Herceptin in Adjuvant Breast Cancer Therapy

Strategic Insights -

A recent study from the University of Ghent in Belgium provides essential information for policymakers considering reimbursement for Herceptin in breast cancer therapy. The study conducted a cost-effectiveness analysis of Herceptin, a humanized monoclonal antibody, in the adjuvant setting for breast cancer. Researchers calculated treatment costs and life expectancy data based on literature, and a threshold analysis was performed to determine an acceptable incremental cost-effectiveness ratio. The study found that treatment costs were significantly attributed to Herceptin, and that its use must be carefully considered due to its high cost and limited availability.

Key Takeaways:

  • The study calculated treatment costs of EUR 45,034 (doxorubicin and cyclophosphamide - docetaxel and trastuzumab) or EUR 47,765 (docetaxel, carboplatin and trastuzumab), which was largely attributed to Herceptin.
  • The researchers performed a threshold analysis to determine an acceptable incremental cost-effectiveness ratio, suggesting that health improvements must be large enough and/or price discounts must be given for Herceptin to be considered cost-effective.
  • The study concluded that Herceptin is a promising but expensive antibody, and that cost implications of its use must be calculated before widespread adoption.
  • The study found that Herceptin is a humanized monoclonal antibody being tested in the adjuvant setting, providing information on the treatment's value for money.
  • The researchers used standard breast cancer treatment models to calculate costs and life expectancy data based on literature, and considered existing practice as a comparator.

Statistics:

  • Treatment costs were EUR 45,034 (doxorubicin and cyclophosphamide - docetaxel and trastuzumab) or EUR 47,765 (docetaxel, carboplatin and trastuzumab).
  • Herceptin attributed to 79% and 75% of treatment costs, respectively.
  • The researchers considered health improvements and price discounts as key factors in determining an acceptable incremental cost-effectiveness ratio.

Sources:

  • Neyt, M., et al. (2006). "An economic evaluation of Herceptin in adjuvant setting: The Breast Cancer International Research Group 006 trial." Annals of Oncology, 17(3), 381-390.
  • University of Ghent, Faculty of Economics and Business Administration, Department of Economics, Hoveniersberg 24, B-9000 Ghent, Belgium.